Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer.

Journal of molecular graphics & modelling - 1 May 2020

Ding Xi, Tong Cheng, Chen Rong, Wang Xi, Gao Dongyun, Zhu Lixia

Abstract excerpt

The oncogenic receptor tyrosine kinase family ErbB consists of four members (ErbB1, ErbB2, ErbB3 and ErbB4); they are involved in the tumorgenesis of diverse cancers. A variety of missence mutations have been clinically observed in ErbB kinases, which would shift drug sensitivity to these kinases and cause drug resistance in targeted cancer therapy. In this study, systematic inhibitor response to ErbB missense...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lapatinib
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation, Missense

Share to Receptor, ErbB-2

Share to Receptor Protein-Tyrosine Kinases

Share to Stomach Neoplasms

Source

Identifiers

PMID: 31901678
DOI: 10.1016/j.jmgm.2019.107526

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer.PMID 31901678Read ↗

Systematic analysis and molecular profiling of EGFR allosteric inhibitor cross-reactivity across the proto-oncogenic ErbB family kinases by integrating dynamics simulation, energetics calculation and biochemical assay.Semantic proximity Read ↗

Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.Semantic proximity Read ↗

Investigating mutations at the hotspot position of the ERBB2 and screening for the novel lead compound to treat breast cancer - a computational approach.Semantic proximity Read ↗

Landscape of drug-resistance mutations in kinase regulatory hotspotsSemantic proximity Read ↗

In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.Semantic proximity Read ↗

Targeting Gatekeeper Mutations for Kinase Drug DiscoverySemantic proximity Read ↗

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.Semantic proximity Read ↗

Potential Resistance to Oxaliplatin-Based Regimens in Gastric Cancer Patients with ERBB2 R678Q Mutation: Evidence from a National Genomic DatabaseSemantic proximity Read ↗

A general framework for inhibitor resistance in protein kinases.Semantic proximity Read ↗

Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations.Semantic proximity Read ↗

Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Semantic proximity Read ↗

Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.